HTP Recombinant Antibody Production HTP Recombinant Antibody Production

HTP Recombinant
Antibody Production

  • 2 Weeks
  • Large Capacity
  • Tailored Services
Home > Antibody Production > HTP Recombinant Antibody Production

Overview

The advancement of antibody discovery technologies like hybridoma, display libraries, Single B-cell sorting/sequencing, and computational modeling has led to the production of thousands of monoclonal antibodies (mAbs). However, identifying the "best-in-class" antibody therapeutics requires rapid assessment using high throughput (HTP) processes.


Biointron’s 2-week high-throughput recombinant antibody production is the leading gene-to-antibody workflow in the industry. We offer the flexibility to rapidly express large amounts of antibodies at varying scales using HEK293 or CHO cells, which are known for efficient recombinant protein production.

HTP Recombinant Antibody Production Overview

Highlights

2 Weeks!

  • 2 Weeks (From sequence to antibody)
  • In-house gene synthesis platform

Large Capacity

  • Automated Working stations
  • Streamlined procedure

Tailored Services

  • No limitations on isotype and species
  • Multiple expression systems

Working Flowchart

Gene Synthesis

Plasmid construction and preparation

Transient expression

Affinity purification

Stringent quality control

Fast delivery

HTP Recombinant Antibody Production
Service Details

Service Step Service Description Timeline Deliverables
Gene synthesis and cloning
  • Codon optimization and gene synthesis
  • Subcloning into an expression vector
  • Plasmid amplification and preparation
1 week
  • Expression plasmid contain GOI
  • Purified antibody (SDS-PAGE >95%, endotoxin level <1EU/mg, including SEC-HPLC report)
  • CoA report
Transient expression & purification
  • Transfection of mammalian cells
  • Transient expression and purification
1 week

Case Study

  • Case 1: 818 Abs (IgG) production
    Yield
    Purity
    Biointron finished the production of all 818 IgGs within 2 weeks.
  • Case 2: VHH antibody expression (Expressing data from 180 VHH-Fc)
    Antibody

    Expression System: CHO、

    SDS-PAGE Purity: > 98%、

    SEC-HPLC Purity: > 95%、

    Deliveries:> 1 mg/VHH antibody、

    Average: 218 mg/L

“I am proud to oversee our featured 2-week high-throughput recombinant antibody production process. Our unrivaled timing does not compromise on quality, and we have 1,700+ happy customers.”
Zhaohao Teng
Zhaohao Teng
HTP Antibody Production Team

FAQs

  • What are recombinant antibodies?

    Recombinant antibodies are monoclonal antibodies produced in vitro through synthetic genes and antibody fragments, instead of using hybridomas. They can take several different formats, such as full-length immunoglobulins (Ig), monovalent antibody fragments such as single-chain fragment variable (scFv) and fragment antigen-binding (Fab), and multimeric diabodies (dimeric scFvs) or triabodies (trimeric scFvs).

  • What is HTP technology?

    High-Throughput Production (HTP) technology involves the use of automated systems and advanced biotechnological methods to produce large quantities of antibodies in a short timeframe. It is essential for meeting the high demand for therapeutic and research antibodies used in various treatments, including cancer therapy, autoimmune diseases, and infectious diseases.

  • Why use HTP methods?

    High-throughput (HTP) recombinant antibody production is the rapid generation of large numbers of recombinant antibodies. This enables the acceleration of research, paving the way towards clinical trials, as well as streamlining the discovery and development processes.

Services & Products

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.